Hanall Biopharma, Institutional Investors Net Buy 117,611 Shares in Last 5 Days... Stock Price at 36,650 KRW (+7.95%)

Hanall Biopharma is trading at 36,650 KRW as of 1:30 PM on the 27th, up 7.95% from the previous day. The trading volume is 2,044,381 shares, which is 55.65% of the previous day's volume. Hanall Biopharma is known as an R&D-focused pharmaceutical and bio company.

On August 26, Jaekyung Park, a researcher at Hi Investment & Securities, stated, "HL161 severe myasthenia gravis Phase 2 clinical trial success. After the announcement, Immunovant (NASDAQ: IMVT) closed up 3.52%. Recently, the success of Argenx's Phase 3 trial, Momenta's Phase 2 trial, and JNJ's $6.5B acquisition of Momenta have led to pre-reflected expectations of clinical success, which limited the rise. The company's stock return is -6.3% compared to the beginning of the year. Even after the dry eye clinical announcement on January 21, 2020, it only reached 35.2%, indicating there is still upside potential." He set Hanall Biopharma's target price at 55,000 KRW.

Over the past five days, individual investors have net sold 60,189 shares of Hanall Biopharma, while foreigners and institutions have net bought 3,663 shares and 117,611 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.